araag2/HINT huggingface dataset:
Clinical trial NCT02529878 (phase 2, status: unknown status)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: s1/paclitaxel chemotherapy plus apatinib
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  unresectable gastric cancer as proven histologically(AJCC, version 7) under any
             following condition: unable radical excision due to the local metastasis of invasion
             metastasis to the lymph node beside the abdominal aorta, non-extensive metastasis to
             liver( not more than three metastatic foci of radical excision), Peritoneal
             metastasis(CY1,P1,P2), kukerburg tumor

          -  Definitely diagnosed as above stage of gastric cancer before operation via CT of MRI,
             ultrasonic endoscopy, PET-CT, or through the laparoscopic exploration if necessary

          -  Untreated(e.g. radiotherapy, chemotherapy, target therapy and immunotherapy)

          -  Negative HER-2 state

          -  ECOG(Eastern Cooperative Oncology Group) :0~2

          -  Age: 18~75 years old

          -  Normal hemodynamic indices before the recruitment(including blood cell count and
             liver/kidney function ). For example: WBC>4.0*109/L, NE>1.5*109/L, PLT>100*109/L,
             BIL<1.5 times of upper limit of normal reference value, ALT and AST<2.5 times of upper
             limit of normal reference value, and CRE<1.2mg/dl

          -  Good cardiac function before the recruitment, no seizure of myocardial infarction in
             past half years, and controllable hypertension and other coronary heart disease

          -  Not concomitant with other uncontrollable benign disease before the recruitment(e.g.
             the infection in the kidney, lung and liver)

          -  Not participating in other clinical trials before and during the treatment

          -  Signed the Informed Consent Form

        Exclusion Criteria:

          -  not conforming above inclusion conditions

          -  Distal metastasis to lung, brain, and bone

          -  Ever operation on the stomach

          -  Operation intolerance due to other systemic basic disease

          -  Ever administrated with other drugs(including TCM drugs) before the recruitment, or no
             guarantee of progress according to the study requirement after recruitment

          -  Allergy to the drugs in this protocol

          -  Pregnant and lactating women

          -  Women at childbearing age and of pregnancy desire during the study
Clinical trial NCT02531113 (phase 2, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: rpc1063
SMILES: CC(C)OC1=CC=C(C=C1C#N)C1=NC(=NO1)C1=CC=CC2=C1CC[C@@H]2NCCO
Eligibility criteria:

        Key Inclusion Criteria:

          -  Crohn's disease (CD) confirmed by endoscopy and histology

          -  Active disease as evaluated by Crohn's Disease Activity Index Score and Simple
             Endoscopic Score for CD

          -  Inadequate response to aminosalicylates, corticosteroids, immunomodulators or biologic
             therapy

        Key Exclusion Criteria:

          -  Diagnosis of ulcerative colitis or indeterminate colitis

          -  Known strictures/stenosis leading to symptoms of obstruction

          -  Current stoma or need for ileostomy or colostomy

          -  Clinically relevant cardiovascular conditions or other relevant diseases that could
             impact the implementation or interpretation of the trial, or put the patient at risk

          -  History of uveitis or known macular edema

          -  History of colonic dysplasia
Clinical trial NCT02536313 (phase 2, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sof/vel/vox, rbv
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Individuals with chronic HCV genotype 1 infection

          -  Documented as treatment experienced with a direct acting antiviral-containing regimen
             without achieving sustained viral response

          -  Absence of cirrhosis or presence of compensated cirrhosis

          -  Screening laboratory values within defined thresholds

          -  Must use specific contraceptive methods if female of childbearing potential or
             sexually active male

        Key Exclusion Criteria:

          -  Co-infection with HIV or hepatitis B virus (HBV)

          -  Current or prior history of clinical hepatic decompensation

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with individual's treatment, assessment or compliance with the protocol

          -  Pregnant or a nursing female

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02536404 (phase 2, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: etrasimod, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who completed the APD334-003 study

        Exclusion Criteria:

          -  Patients who did not complete the APD334-003 study
Clinical trial NCT02541396 (phase 2, status: completed)
Conditions: acute pain
ICD codes: G89.12, G89.18, G89.11, G89.3
Drugs: wafermine, oxycodone, placebo
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Scheduled for a bunionectomy (with no additional procedures).

          -  Healthy, ambulatory subjects able to understand and willing to comply with study
             procedures, study restrictions and requirements.

          -  Body mass index (BMI) ≥19 to ≤33 kg/m2.

          -  Females: Not pregnant, not lactating, and not planning to become pregnant during the
             study.

          -  Females: Be abstinent, surgically sterile, at least two years post-menopausal; or
             medically acceptable contraception.

          -  Able to read and understand English.

          -  Able to swallow oral capsules whole.

        Exclusion Criteria:

          -  Allergy, intolerance, or contraindication to ketamine, oxycodone, morphine, ibuprofen
             or surgical medications.

          -  Clinically significant medical condition.

          -  History of illicit drug use or alcohol abuse and not in full remission.

          -  Positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or
             hepatitis C virus (HCV) at the screening visit.

          -  Clinically significant 12 lead ECG abnormalities at screening.

          -  Smokers who are unwilling to abstain during the inpatient stay.
Clinical trial NCT02542215 (phase 2, status: terminated)
Conditions: oral mucositis
ICD codes: K12.30, K12.39, K12.33, K12.31, K12.32
Drugs: cobiprostone, placebo, standard care - chemotherapy
SMILES: CC[C@H](C)CC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(O)=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Recently-diagnosed (within the last 6 months), histologically-documented,
             non-metastatic squamous cell carcinoma of the oral cavity and/or oropharynx amenable
             to radiotherapy with concurrent chemotherapy as the definitive treatment modality.

          -  Clinical treatment plan calls for a minimum of 50 Gy cumulative radiation dose
             administered via continuous course of external beam irradiation to the oral cavity
             and/or oropharynx via intensity-modulated radiation therapy (IMRT) and/or image-guided
             radiation therapy (IGRT), combined with conventional or weekly/tri-weekly cisplatin or
             carboplatin chemotherapy regimen.

        Exclusion Criteria:

          -  Subject has received prior radiation to the head and neck region (+/- chemotherapy).

          -  Subject has had any other prior invasive malignancy, unless disease-free for a minimum
             of 3 years.

          -  Subject has metastatic disease (M1) Stage IV-C.

          -  Subject has a presence of mucosal ulceration or oral mucositis at screening or
             develops this prior to randomization, and/or has unhealed wounds remaining from
             surgical resection and/or excisional biopsy procedure.

          -  Subject is using a pre-existing feeding tube for nutritional support at study entry.
Clinical trial NCT02547935 (phase 2/phase 3, status: completed)
Conditions: type 2 diabetes mellitus, ckd and albuminuria
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: dapagliflozin 10 mg, saxagliptin 2.5 mg, matching placebo for dapagliflozin 10 mg and saxagliptin 2.5mg
SMILES: CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1, N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Female or male aged ≥18 years

          -  History of type 2 diabetes mellitus for more than 12 months

          -  HbA1c≥7.0% and ≤11.0%

          -  Stable antidiabetic treatment during the last 12 weeks up to randomization

          -  eGFR 25-75 mL/minute/1.73m2, inclusive

          -  Micro or macroalbuminuria (UACR 30 - 3500 mg/g)

          -  Treatment with ACE inhibitor or an ARB for at least 3 months prior to screening

          -  Body mass index between 20 and 45 kg/m2

        Exclusion Criteria:

          -  Any of the following CV/Vascular Diseases within 3 month prior to signing the consent
             at Visit 1:

               -  Myocardial infarction

               -  cardiac surgery or revascularization (CABG/PTCA)

               -  unstable angina

               -  unstable HF

               -  New York Heart Association (NYHA) Class III-IV

               -  transient ischemic attack (TIA) or significant cerebrovascular disease

               -  unstable or previously undiagnosed arrhythmia

          -  Significant hepatic disease, including, but not limited to, chronic active hepatitis
             and/or severe hepatic insufficiency

          -  Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) > 3X ULN

          -  Total Bilirubin (TB) >2 mg/dL (34.2 μmol/L)

          -  History of acute kidney injury requiring renal replacement therapy (dialysis or
             ultrafiltration) or any biopsy or imaging verifying intercurrent kidney disease other
             than diabetic nephropathy or diabetic nephropathy with nephrosclerosis

          -  Ongoing treatment with a SGLT2 inhibitor, GLP-1 agonist or DPP4 inhibitors

          -  Any condition which, in the judgment of the Investigator, may render the patient
             unable to complete the study or which may pose a significant risk to the patient or
             patient suspected or with confirmed poor protocol or medication compliance
Clinical trial NCT02549391 (phase 2/phase 3, status: completed)
Conditions: secondary hyperparathyroidism
ICD codes: E21.1, N25.81
Drugs: khk7580, krn1493
SMILES: C[C@@H](N[C@H]1CCN(C1)C1=CC=C(CC(O)=O)C=C1)C1=C2C=CC=CC2=CC=C1, C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Personally submitted written voluntary informed consent to participate in the study

          -  Stable chronic renal disease treated with hemodialysis 3 times weekly for at least 12
             weeks before screening

          -  Mean intact PTH level of > 240 pg/ml at screening, at 2 weeks and 1 week before the
             start of study treatment

        Exclusion Criteria:

          -  Treatment with cinacalcet hydrochloride within 2 weeks before screening;

          -  Change in dose or dosing regimen of an activated vitamin D drug or its derivative,
             phosphate binder, or calcium preparation within 2 weeks before screening; or start of
             treatment with such drugs within 2 weeks before screening;

          -  Parathyroidectomy and/or parathyroid intervention within 24 weeks before screening;

          -  Severe heart disease;

          -  Severe hepatic dysfunction;

          -  Uncontrolled hypertension and/or diabetes;

          -  Treatment with an investigational product (drug or medical device) in a clinical study
             or any study equivalent to clinical study within 12 weeks before screening;

          -  Primary hyperparathyroidism;

          -  Other conditions unfit for participation in this study at the discretion of the
             investigator or subinvestigator.
Clinical trial NCT02550418 (phase 2, status: completed)
Conditions: colitis, ulcerative
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: budesonide
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent,

          -  Men or women aged 18 to 75 years,

          -  Active ulcerative colitis, except proctitis limited to 15 cm ab ano, confirmed by
             endoscopy and histology,

          -  Established disease,

        Exclusion Criteria:

          -  Crohn's disease, indeterminate colitis, ischaemic colitis, radiation colitis,
             microscopic colitis (i.e., collagenous colitis and lymphocytic colitis, incomplete
             microscopic colitis), diverticular disease associated colitis,

          -  Toxic megacolon or fulminant colitis,

          -  Colon resection,

          -  Evidence of infectious colitis (e.g., pathogenic bacteria or Clostridium difficile
             toxin in stool culture at screening),

          -  Malabsorption syndromes,

          -  Celiac disease,

          -  Bleeding hemorrhoids,

          -  Active peptic ulcer disease

          -  Other inflammatory or bleeding disorders of the colon and intestine, or diseases that
             may cause diarrhea or gastrointestinal bleeding,

          -  Hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma,
             cataract, or infection if careful medical monitoring is not ensured,

          -  Any severe infectious disease (e.g., tuberculosis, AIDS),

          -  Severe co-morbidity substantially reducing life expectancy,

          -  History of colorectal cancer,

          -  History of cancer (other than colorectal) in the last 5 years, except for basal cell
             carcinoma
Clinical trial NCT02550977 (phase 2, status: completed)
Conditions: contraception
ICD codes: Z92.0, Z30.012, Z30.09
Drugs: gestodene/ee patch (bay86-5016)
SMILES: CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy female subjects requesting contraception

          -  Aged 18 to 35 years (inclusive); smokers must not be older than 30 years

          -  Normal or clinically insignificant cervical smear not requiring further follow-up

          -  History of regular cyclic menstrual periods

          -  Willingness to use nonhormonal methods of contraception during the entire study

          -  Proven ovulation upon completion of the pretreatment cycle

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Obesity (body mass index [BMI] > 30.0 kg/m2)

          -  Significant skin reaction to transdermal preparations or sensitivity to
             surgical/medical tape

          -  Any disease or condition that may worsen under hormonal treatment

          -  Use of hormonal contraception other than study medication during the study
Clinical trial NCT02551809 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of mild Alzheimer's Disease

          -  Mini-Mental State Examination (MMSE) scores between 20 and 26 (inclusive)

          -  Clinical dementia rating (CDR) scores of 0.5 or 1

          -  Other inclusion criteria apply

        Exclusion Criteria:

          -  Clinically significant neurological disease other than Alzheimer's disease

          -  Major psychiatric disorder

          -  Severe systemic disease

          -  Serious adverse reactions to any vaccine

          -  Other exclusion criteria apply
Clinical trial NCT02553889 (phase 2, status: completed)
Conditions: end-stage renal disease (esrd)
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: isis 416858, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  End stage renal disease maintained on outpatient hemodialysis at a healthcare center
             for > 3 months from screening with hemodialysis using heparin (unfractionated heparin
             or low-molecular weight heparin) 3 times per week for a minimum of 3 hours per
             dialysis session and plan to continue this throughout the study.

        Exclusion Criteria:

          -  Documented thrombotic event (acute coronary syndrome, stroke or transient ischemic
             attack, venous thromboembolic event) in the past 3 months.

          -  Active bleeding within the past 3 months from screening or documented bleeding
             diathesis (history of bleeding disorder) or Screening values of:

               -  Platelet count < 150,000 cells/mm3

               -  INR > 1.4

               -  aPTT > upper limit of normal (ULN)

          -  Abnormal liver function at Screening:

               -  ALT or AST > 2 x ULN

               -  Total bilirubin > ULN

          -  Concomitant medication restrictions: Concomitant use of anticoagulant/antiplatelet
             agents (e.g., dabigatran, rivaroxaban, clopidogrel) that may affect coagulation
             (except low dose aspirin (≤ 100 mg/day) during Treatment and Post-treatment Evaluation
             Periods is not allowed.

          -  Uncontrolled hypertension as judged by the Investigator. Patients with a pre- or
             post-dialysis blood pressure (BP) that is > 160 mmHg on at least 3 of last 5 dialysis
             treatments.

          -  Planned major surgery in the next 6 months (e.g. renal transplant surgery)
Clinical trial NCT02557126 (phase 2, status: completed)
Conditions: gout, hyperuricemia
ICD codes: M10.9, M10.08, M10.00, M10.011, M10.012, M10.019, M10.021, E79.0
Drugs: urc102, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with gout

        Exclusion Criteria:

          -  Participated in other clinical study within 12 weeks prior to enrollment, and received
             an investigational product (including placebo)
Clinical trial NCT02559206 (phase 2, status: completed)
Conditions: irritable bowel syndrome with constipation
ICD codes: K58.1
Drugs: linaclotide, matching placebo
SMILES: [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has completed a colonoscopy according to the American Gastroenterological
             Association (AGA) criteria, with no clinically significant findings

          -  Patient has no clinically significant findings on a physical examination and clinical
             laboratory tests

          -  Patient meets protocol criteria for diagnosis of IBS-C

          -  Patient demonstrates continued IBS-C through Pretreatment Period

          -  Patient maintains a minimum level of compliance with daily diary

        Exclusion Criteria:

          -  Patient has history of loose or watery stools

          -  Patient has symptoms of or been diagnosed with a medical condition that may contribute
             to abdominal pain

          -  Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease
             or condition that can affect GI motility

          -  Patient has any protocol-excluded or clinically significant medical or surgical
             history that could confound the study assessments
Clinical trial NCT02562651 (phase 2/phase 3, status: unknown status)
Conditions: vascular diseases, cardiovascular diseases, acute myocardial infarction
ICD codes: I73.9, D57.03, D57.213, G46.8, I73.89, A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30, I21.9, I23.8, I23.0, I24.0, I23.1, I23.2, I23.4
Drugs: doxycycline
SMILES: [H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Eligibility criteria:

        Inclusion Criteria:

          -  age ≥ 18 and ≤ 75 years at time of randomization (18 years and older)

          -  ST-elevation Q wave myocardial infarction

          -  term admission to an intensive care unit (ICU) in the first 24 hours of onset

          -  the reperfusion of the infarct-related coronary artery is not later than 24 hours
             after the initial onset of acute transmural myocardial infarction

          -  written the informed consent to participate in research

        Exclusion Criteria:

          -  atrial fibrillation, a permanent form

          -  valvular heart disease

          -  severe comorbidity

          -  acute heart failure according to the Killip classification IV FC (functional class)

          -  history of chronic heart failure (NYHA III-IV)

          -  poor image quality for Echocardiography

          -  sinus bradycardia - heart rate of under 50 beats per minute, interventricular
             conduction delay (QRS > 0,11 s.) and atrioventricular block II-III degree